MARKET

CRNX

CRNX

Crinetics Pharmaceuticals
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.19
+0.10
+0.66%
After Hours: 15.19 0 0.00% 16:00 01/20 EST
OPEN
14.75
PREV CLOSE
15.09
HIGH
15.36
LOW
14.75
VOLUME
91.06K
TURNOVER
--
52 WEEK HIGH
24.46
52 WEEK LOW
10.63
MARKET CAP
500.09M
P/E (TTM)
-6.3522
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Crinetics Pharmaceuticals to Review 2020 Accomplishments and Provide 2021 Plans at 39th Annual J.P. Morgan Healthcare Conference
- Paltusotine planned to advance to a pivotal Phase 3 trial in acromegaly in H1 2021 -
GlobeNewswire · 01/06 12:05
Crinetics Pharmaceuticals to Review 2020 Accomplishments and Provide 2021 Plans at 39th Annual J.P. Morgan Healthcare Conference
\- Paltusotine planned to advance to a pivotal Phase 3 trial in acromegaly in H1 2021 - \- Initiation of Phase 1 proof-of-concept study evaluating CRN04894 for the treatment of congenital adrenal hyperplasia and Cushing’s disease expected in January 2021 ...
GlobeNewswire · 01/06 12:05
ISR, CRNX, MXC and CLSD among after-hours movers
Gainers: [[ISR]] +67.9%. [[CRNX]] +7.9%. [[SCPE]] +6.3%. [[SCYX]] +6.1%. [[ENSV]] +5.3%.Losers: [[MXC]] -11.5%. [[CLSD]] -10.0%. [[DWSN]] -9.9%. [[IRIX]] -8.9%. [[TITN]] -6.6%.
Seekingalpha · 01/05 22:34
Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation
Simply Wall St. · 12/27/2020 06:37
Is CRNX A Good Stock To Buy Now?
Insider Monkey · 12/16/2020 04:26
RIDE, FATE, MBIO and MRIN among after-hours movers
Gainers: [[OBLN]] +81%. [[MRIN]] +9.8%. [[FATE]] +8.8%. [[CRNX]] +6.7%. [[PROG]] +6.1%.Losers: [[HX]] -6.2%. [[INN]] -6.2%. [[RIDE]] -5.6%. [[MBIO]] -4.4%. [[EVK]] -3.8%.
Seekingalpha · 12/04/2020 22:52
Crinetics Pharmaceuticals to Participate in December Investor Conferences
Crinetics Pharmaceuticals(Nasdaq: CRNX), today announced that company management will participate in the following conferences in the month of December. Please see additional details below:
GlobeNewswire · 11/23/2020 12:51
Crinetics Pharmaceuticals to Participate in December Investor Conferences
Crinetics Pharmaceuticals(Nasdaq: CRNX), today announced that company management will participate in the following conferences in the month of December. Please see additional details below:
GlobeNewswire · 11/23/2020 12:51
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CRNX. Analyze the recent business situations of Crinetics Pharmaceuticals through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CRNX stock price target is 33.60 with a high estimate of 42.00 and a low estimate of 23.00.
EPS
Institutional Holdings
Institutions: 103
Institutional Holdings: 32.27M
% Owned: 98.02%
Shares Outstanding: 32.92M
TypeInstitutionsShares
Increased
22
680.67K
New
18
-1.18M
Decreased
24
621.54K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.31%
Pharmaceuticals & Medical Research
-0.03%
Key Executives
Chairman/Independent Director
Wendall Wierenga
President/Chief Executive Officer/Director
R. Scott Struthers
Chief Financial Officer
Marc Wilson
Vice President/Director of Human Resources
Adriana Cabre
Vice President
Peter Trainer
Other
Alan Krasner
Other
Ajay Madan
Independent Director
Camille Bedrosian
Independent Director
Matthew Fust
Independent Director
Stephen Kaldor
Independent Director
Weston Nichols
Independent Director
Stephanie Okey
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CRNX
Crinetics Pharmaceuticals, Inc. is a clinical stage pharmaceutical company. The Company is focused on the discovery and development of drugs to treat specialty endocrine diseases and endocrine-related tumors. It develops a pipeline of oral nonpeptide chemical entities that target peptide G protein coupled receptors (GPCRs) for the treatment of endocrine diseases. The Company’s lead product candidate is CRN00808 developed for the treatment of acromegaly. It also develops two other product candidates CRN02481 for hyperinsulinemia, and CRN01941 for the treatment of neuroendocrine tumors. CRN02481 and CRN01941 are both oral nonpeptide somastatin receptors that are in the pre-clinical stages of development. The company also conducts research programs on developing nonpeptide products for the treatment of Cushing’s disease.
More

Webull offers kinds of Crinetics Pharmaceuticals Inc stock information, including NASDAQ:CRNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRNX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRNX stock methods without spending real money on the virtual paper trading platform.